Utilization and revenue were half of March and April 2019 levels for oral surgery, cardiology, dermatology, gastroenterology, and orthopedics.
We know that people stopped going to the doctor when COVID-19 hit in March. FAIR Health, a not-for-profit with a large database that includes 150 million insured Americans and claims from 60 insurers and third-party administrators, put some numbers to that generalization in a report today.
Overall, the report shows that utilization of professional services declined by 65% in March 2020 compared with March 2019 and revenue (which FAIR Health calculates based on estimates of in-network fees) for the month flew 45%. In April, the drop-off was even steeper: a 68% decrease in utilization compared with April 2019 and a 48% decline in revenue.
The FAIR Health researchers also looked at seven specialties. Oral surgery had the largest declines in utilization and revenue while pediatric primary care had smallest. Cardiology, dermatology, gastroenterology and orthopedics all saw utilization and revenue declines in March and April of well over 50% compared with those months a year ago. Pediatric and adult primary care also saw steep declines but not as steep as the declines for those four specialties
FAIR Health’s data showed little change in preventive care for newborns and children through the age of four. There has been some concern that other kinds of infectious diseases might take off if children stopped getting vaccinated. The FAIR Health claims data show some drop off in vaccinations - 14% decline in March compared with March 2019 and 10% decline in April compared with April 2019 – but decrease wasn’t as precipitous as many feared.
The report notes that evaluation and management (E&M) visits became more common relative to other procedures, both by utilization and revenue estimates. The report attributes the change to telehealth and the decline in procedures that require in-person care.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
ICER Identifies 5 Drugs with Unsupported Price Increases
December 12th 2024The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and Xeljanz — with prices increases that are not supported by new clinical evidence, with a total of $815 million in added costs to U.S. payers in 2023.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen